The presentation included updates to its financial guidance, and a peek into management’s plans for its drug pipeline. Are Celgene’s best days ahead of it? Over the past five years, Celgene’s sales and earnings per share have grown by a compounded 20% and 25% per year, respectively, and based on management’s updated financial guidance, that double-digit growth isn’t going to end anytime soon.